http://circoutcomes.ahajournals.org/content/10/1/e003438?etoc=
This article requires a subscription to view the full text. If
you have a subscription you may use the login form below to view the
article. Access to this article can also be purchased.
Stroke
is a time-sensitive medical emergency and a leading cause of disability
in the United States. Therapies to halt and even reverse ischemic
injury to the brain, such as intravenous tissue-type plasminogen
activator (tPA), are available, but the systems to deliver them rapidly
have not been optimized to ensure timely treatment of as many eligible
patients as possible. Although ≈40 000 to 50 000 acute ischemic stroke
patients per year receive tPA,1,2
benefits from the drug are not simply related to receiving it or not
but rather are closely linked to time from onset to treatment.3,4
Delays to treatment lead to more disability because every additional 5
minutes is tantamount to the permanent loss of nearly 10 million brain
cells.5 National guidelines
and quality measures have, therefore, emphasized speed of stroke
thrombolysis, focusing on the time between patient arrival to the
hospital and tPA administration, also known as door-to-needle (DTN)
time.6,7
Alarmingly, recommendations that hospitals evaluate acute ischemic
stroke patients and administer tPA within 60 minutes(Wrong goal)of a patient’s
arrival to the emergency department have existed since the original
National Institutes of Neurological Disorders and Stroke tPA trial.8
Despite this, as the first decade of the new millennium closed, US
hospitals were not meeting this goal in a majority of patients.
No comments:
Post a Comment